Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI could spot hidden heart disease without extra needles

NCT ID NCT07676097

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether an artificial intelligence system called AngioAI+ can accurately diagnose two types of coronary artery disease using standard angiogram images. The research involves 620 adults with suspected coronary artery disease who are already scheduled for an angiogram. The AI's results will be compared to traditional invasive measurements to see if it can reliably detect blockages and microvascular disease, potentially reducing the need for additional procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AngioAI+ software (artificial intelligence diagnostic tool)
What this could lead to
If successful, this AI tool could help doctors diagnose coronary artery disease and microvascular problems without extra invasive tests, making diagnosis faster and safer.
What could go wrong
This is an observational study testing the software's accuracy against existing methods. The AI may not perform as well in real-world settings or on all patient types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 620 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with acute or chronic coronary artery disease

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with acute or chronic coronary syndromes referred for invasive coronary angiography with clinically indicated coronary physiologic assessment. In patients with acute coronary syndromes, the physiological evaluation will be restricted to non-culprit vessels. * Patients with intermediate CAD (30-90% visual stenosis) with clinically indicated FFR assessment. * Patients with NOCAD (\<30% visual stenosis) with clinically indicated microvascular assessment. Exclusion Criteria: * Patients presenting with ST-elevation * Prior myocardial infarction in the target vessel * Stent implantation in the target vessel within the last 12 months * Previous coronary artery bypass grafting surgery (CABG) * Previous heart valve surgery * Previous heart transplantation * Moderate-to-severe valvular disease * Left ventricular ejection fraction (EF) ≤45% * Hemodynamic instability or cardiogenic shock Angiographic Exclusion Criteria * Left main stenosis≥50% * Chronic total occlusion in the target vessel * CTO in a non-target vessel * Less than thrombolysis in myocardial infarction (TIMI) 3 flow in the target vessel * Target vessel receiving collaterals * Inadequate coronary angiographic images * Ostial lesions * Severe tortuosity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute or chronic coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ascension Saint Thomas

    Nashville, Tennessee, 37205, United States

  • Christ Hospital

    Cincinnati, Ohio, 45219, United States

  • Minneapolis Heart

    Minneapolis, Minnesota, 55407, United States

  • New York University

    New York, New York, 10016, United States

  • Northwell Health

    New York, New York, 10075, United States

  • Palo Alto Veterans Administration Hospital

    Palo Alto, California, 94304, United States

  • Stanford University

    Palo Alto, California, 94304, United States

  • Valley Health System

    Paramus, New Jersey, 07652, United States

  • Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States